文献速递心力衰竭与心肌病

心衰住院患者心血管-肾脏-代谢重叠负担与预后

Cardiovascular-Kidney-Metabolic Overlap in Patients Hospitalized for Heart Failure.
PubMed 文献 · JAMA Cardiol · 2026-09-30

结果显示大多数心衰住院患者存在多重CKM重叠,CKM共病数量增加与死亡和再入院风险呈阶梯式上升,且对射血分数降低的心衰影响最大。

要点

  • 多数心衰住院患者存在多重CKM共病,仅少数为单纯心衰。
  • CKM共病数量越多,院内死亡和出院后死亡、心衰再入院风险越高。
  • CKM共病对HFrEF预后影响最大,对HFpEF影响相对最小。

核心结论

  • 在当代美国心衰住院患者中,大多数患者合并多种额外CKM共病,CKM多重共病增加与死亡和再入院风险阶梯式上升独立相关。
  • CKM共病的预后影响贯穿整个射血分数谱,但在HFrEF中最大,在HFpEF中最小。

研究设计与样本

  • 回顾性队列研究,数据来自美国GWTG-HF注册研究中2019至2025年住院心衰患者及2019至2023年Medicare受益人。

主要发现

  • CKM重叠在射血分数保留的心衰(HFpEF)中最为显著。
  • 与单纯心衰相比,CKM共病数量增加与院内死亡率阶梯式升高相关,4种CKM共病时HFrEF的aOR为5.08(95% CI,4.43-5.83),HFmrEF的aOR为2.37(95% CI,1.68-3.34),HFpEF的aOR为2.05(95% CI,1.77-2.38)。
  • 在Medicare受益人中,与单纯心衰相比,4种CKM共病时出院后全因死亡的aHR为HFrEF 2.10(95% CI,1.93-2.29)、HFmrEF 1.38(95% CI,1.17-1.63)、HFpEF 1.09(95% CI,1.03-1.17)。
  • 在Medicare受益人中,4种CKM共病时心衰再入院的aHR为HFrEF 2.33(95% CI,2.12-2.56)、HFmrEF 2.20(95% CI,1.82-2.66)、HFpEF 1.91(95% CI,1.77-2.06)。

关键数值与推荐

  • CKM共病包括动脉粥样硬化性心血管疾病、慢性肾脏病、糖尿病和肥胖(体重指数≥30,按体重公斤数除以身高米数平方计算)。
  • 研究终点包括院内全因死亡、出院后1年全因死亡和出院后1年心衰再入院。

临床怎么用

  • 心衰住院患者应系统评估CKM共病负担,即使射血分数保留的心衰患者中CKM重叠比例也很高。
  • 对合并多种CKM共病的HFrEF患者应加强出院后管理和随访,以降低死亡和再入院风险。

局限性

  • 研究为注册研究回顾性分析,院内死亡率相关分析基于GWTG-HF全队列,而出院后结局仅纳入Medicare受益人。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Among patients with heart failure (HF) in contemporary US clinical practice, the burden of overlapping cardiovascular-kidney-metabolic (CKM) conditions and the associated impact on outcomes remain poorly characterized. OBJECTIVE: To evaluate the prevalence of CKM multimorbidity and the impact on clinical outcomes in patients hospitalized for HF across the spectrum of ejection fraction (EF). DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study of patients hospitalized for HF at US hospitals participating in the Get With The Guidelines-Heart Failure (GWTG-HF) registry. The analysis included patients hospitalized for HF in the GWTG-HF registry between 2019-2025 and Medicare beneficiaries hospitalized for HF in the GWTG-HF registry between 2019-2023. EXPOSURES: Presence of up to 4 additional CKM conditions including atherosclerotic cardiovascular disease, chronic kidney disease, diabetes, and obesity (body mass index ≥30; calculated as weight in kilograms divided by height in meters squared). MAIN OUTCOMES AND MEASURES: In-hospital mortality, 1-year postdischarge all-cause mortality, and 1-year postdischarge HF readmission. RESULTS: This study included 725 205 patients (median [IQR] age, 72.0 [61.0-82.0] years; 386 886 male [53.3%]) hospitalized for HF between 2019 and 2025 and 123 271 Medicare beneficiaries (median [IQR] age, 80 [73-87] years; 64 375 female [52.2%]) hospitalized for HF between 2019 and 2023. Among 725 205 patients hospitalized for HF, 521 739 (71.9%) had 2 or more overlapping CKM conditions, and a minority of patients (48 732 [6.7%]) had HF only. CKM overlap was greatest in HF with preserved EF (HFpEF). Compared with HF only, increasing number of overlapping CKM conditions was associated with stepwise increases in in-hospital mortality (4 CKM conditions: HF with reduced EF [HFrEF] adjusted odds ratio [aOR], 5.08; 95% CI, 4.43-5.83; HF with mildly reduced EF [HFmrEF] aOR, 2.37; 95% CI, 1.68-3.34; HFpEF aOR, 2.05; 95% CI, 1.77-2.38), and this association was strongest in HFrEF (P for interaction <.001). Among Medicare beneficiaries hospitalized for HF, compared with HF only, increasing CKM multimorbidity was associated with increasing risks of postdischarge all-cause mortality (4 CKM conditions: HFrEF adjusted hazards ratio [aHR], 2.10; 95% CI, 1.93-2.29; HFmrEF aHR, 1.38; 95% CI, 1.17-1.63; HFpEF aHR, 1.09; 95% CI, 1.03-1.17) and HF readmission (4 CKM conditions: HFrEF aHR, 2.33; 95% CI, 2.12-2.56; HFmrEF aHR, 2.20; 95% CI, 1.82-2.66; HFpEF aHR, 1.91; 95% CI, 1.77-2.06), with steepest increases in risk among patients with HFrEF (P for interaction <.001). CONCLUSIONS AND RELEVANCE: In this contemporary cohort of US patients hospitalized for HF, most patients had multiple additional overlapping CKM conditions. Increasing CKM multimorbidity was independently associated with stepwise increases in mortality and readmission risk. Although these associations spanned the EF spectrum, the prognostic impact of CKM multimorbidity was greatest in HFrEF and least in HFpEF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Kittipibul, Ayodele, Fonarow, et al. Cardiovascular-Kidney-Metabolic Overlap in Patients Hospitalized for Heart Failure. JAMA Cardiol. 2026. PMID: 42814450. doi:10.1001/jamacardio.2026.4215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。